Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30074396 | 0.84 | EPHX2 (0.65) | EPHX2MAPTTRPV1KMT2AKDM4E | |
| SCHEMBL21580276 | 0.83 | ALDH1A1 (0.55) | EPHX2MAPTNPC1TSHRHPGD | |
| SCHEMBL28533796 | 0.82 | EPHX2 (0.58) | EPHX2MAPTTRPV1KMT2AKDM4E | |
| SCHEMBL12857266 | 0.82 | EPHX2 (0.60) | EPHX2TRPV1 | |
| SCHEMBL1160609 | 0.80 | EPHX2 (0.59) | EPHX2TRPV1 | |
| Hydrochloric Acid SCHEMBL1159681 | 0.80 | EPHX2 (0.58) | EPHX2TRPV1 | |
| SCHEMBL1160481 | 0.80 | EPHX2 (0.57) | EPHX2TRPV1NPC1 | |
| SCHEMBL27972397 | 0.80 | NPC1 (0.58) | MAPTTRPV1KDM4ESMN1; SMN2FAAH | |
| SCHEMBL21580336 | 0.80 | THRB (0.60) | EPHX2MAPTTRPV1FAAHNPC1 | |
| Hydrochloric Acid SCHEMBL1160699 | 0.79 | EPHX2 (0.56) | EPHX2TRPV1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370761-B2 | Voltage-dependent T-type calcium channel inhibitor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-06-28 | — | — | US | disclosed |
| US-20210323930-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | KINKI UNIVERSITY (JP) | 2021-10-21 | — | — | US | disclosed |
| EP-3572403-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2019-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370761-B2 | Voltage-dependent T-type calcium channel inhibitor | CACNA1I, CACNA1G, CACNA1H | EPHX2 4298/4885MAPT 176/4885TRPV1 46/4885 |
| US-20210323930-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | EPHX2 4298/4885MAPT 176/4885TRPV1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.